US Broker Ratings

QuidelOrtho Corporation (QDEL) Stock Analysis: Exploring a 127% Potential Upside Amidst Market Challenges

QuidelOrtho Corporation (NASDAQ: QDEL) is a prominent player in the healthcare sector, specifically within the medical devices industry. Based in San Diego, California, the company specializes in providing cutting-edge diagnostic..

MiMedx Group, Inc (MDXG) Stock Analysis: Unpacking a Potential 150% Upside in Biotechnology

MiMedx Group, Inc (NASDAQ: MDXG), a pioneering player in the biotechnology sector, is capturing investor attention with its significant potential upside of 150.43%. With a robust presence in the healthcare..

U.S. Physical Therapy (USPH) Stock Analysis: 39% Potential Upside Beckons Investors

U.S. Physical Therapy, Inc. (NYSE: USPH) is carving out a significant niche within the healthcare sector, specifically in the Medical Care Facilities industry. With a market capitalization of $1.14 billion,..

AtriCure, Inc. (ATRC) Investor Outlook: Exploring a 71.87% Potential Upside Amid Market Challenges

With its focus on surgical solutions in the medical instruments and supplies industry, AtriCure, Inc. (ATRC) stands as a pivotal player in the healthcare sector, offering a range of innovative..

Dynavax Technologies Corporation (DVAX) Stock Analysis: Potential Upside Amidst Vaccine Innovation

Dynavax Technologies Corporation (DVAX), a biopharmaceutical entity headquartered in Emeryville, California, is carving a significant niche within the healthcare sector. With a market capitalization of $1.82 billion, this company is..

CG Oncology, Inc. (CGON) Stock Analysis: Exploring a 30% Upside Potential Amidst Strong Buy Ratings

CG Oncology, Inc. (NASDAQ: CGON), a prominent player in the biotechnology industry, has captured investor attention with its pioneering work in oncolytic immunotherapy, specifically targeting bladder cancer. Headquartered in Irvine,..

Alphatec Holdings, Inc. (ATEC) Stock Analysis: Unpacking a 121.97% Potential Upside in the Medical Devices Sector

Alphatec Holdings, Inc. (NASDAQ: ATEC) has emerged as a noteworthy player in the medical devices industry, particularly in the realm of spinal disorder treatments. Based in Carlsbad, California, this healthcare..

GoodRx Holdings, Inc. (GDRX) Stock Analysis: Unveiling a Potential 47.40% Upside in Health Information Services

GoodRx Holdings, Inc. (NASDAQ: GDRX) is a standout player in the healthcare sector, specifically within the health information services industry. Known for its innovative approach to prescription drug price comparison,..

UFP Technologies, Inc. (UFPT) Investor Outlook: Exploring a 73.75% Upside Potential

UFP Technologies, Inc. (NASDAQ: UFPT), a key player in the healthcare sector, specifically within the medical devices industry, is capturing investor attention with its robust growth prospects and significant upside..

Twist Bioscience Corporation (TWST) Stock Analysis: Exploring a Potential 16.61% Upside in the Synthetic DNA Market

Twist Bioscience Corporation (NASDAQ: TWST), a frontrunner in the synthetic DNA landscape, presents an intriguing opportunity for investors with a potential upside of 16.61%, as indicated by its average analyst..

Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: Strong Buy Ratings Signal 42.62% Upside Potential

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical trailblazer in the healthcare sector, is capturing investor attention with its focus on rare and orphan diseases. With a market capitalization of $5.3..

Progyny, Inc. (PGNY) Stock Analysis: Exploring a 61.78% Potential Upside in the Healthcare Sector

Progyny, Inc. (PGNY), a prominent player in the healthcare sector specializing in fertility benefits management, has been capturing investor attention with its promising potential upside of 61.78%. As a company..

Structure Therapeutics Inc. (GPCR) Stock Analysis: Exploring a 148% Potential Upside

Structure Therapeutics Inc. (NASDAQ: GPCR) is attracting considerable attention in the biotechnology sector, primarily due to its promising pipeline focused on chronic diseases with unmet medical needs. As a clinical-stage..

ACADIA Pharmaceuticals (ACAD) Stock Analysis: Exploring a 51% Potential Upside

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a prominent player in the biotechnology industry, is capturing investor attention with its promising portfolio in the healthcare sector. The San Diego-based company, with a..

Liquidia Corporation (LQDA) Stock Analysis: Evaluating a 44% Potential Upside in Biopharmaceutical Innovator

Liquidia Corporation (NASDAQ: LQDA), a promising player in the biopharmaceutical sector, is capturing investor attention with its innovative approach to treating rare cardiopulmonary diseases. With a market capitalization of $3.1..

ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: A Promising 245% Upside in the Biotech Arena

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a notable player in the biotechnology sector, has been capturing investor interest with its innovative approach to treating severe allergic reactions. Headquartered in San Diego,..

Ocular Therapeutix, Inc. (OCUL) Stock Analysis: Exploring a Potential 251% Upside

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a prominent player in the biotechnology sector, is drawing investor attention with an enticing potential upside of 251.35%. With its focus on innovative treatments for..

Celldex Therapeutics (CLDX) Stock Analysis: A Biotech Gem with 84% Upside Potential

For investors seeking a foothold in the biotechnology sector, Celldex Therapeutics, Inc. (NASDAQ: CLDX) presents a compelling opportunity. With a market capitalization of $1.96 billion, Celldex is positioned at the..

Novavax, Inc. (NVAX) Investor Outlook: Potential Upside of Over 70% with Growing Revenue

Novavax, Inc. (NASDAQ: NVAX), a prominent player in the biotechnology sector, has recently captured investor attention with its substantial potential upside of 70.31%. As a company devoted to the discovery,..

Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: A Biotech Contender with 42% Upside Potential

In the ever-evolving landscape of biotechnology, Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) stands out as a promising player, particularly in the field of eye care. With a market capitalization of $2.85..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds